Aarti Pharmalabs has reported its financial performance for the quarter and year ended March 31, 2026. The board has recommended a final dividend of Rs. 2/- per equity share (40% of face value), subject to shareholder approval. The company also announced key leadership appointments, designating new Senior Management Personnel effective May 25, 2026, to further strengthen its operations and global market outreach.
Financial Performance Summary
For the fiscal year ended March 31, 2026, Aarti Pharmalabs reported robust financial growth. The company achieved a consolidated total income of Rs. 182,918.89 lakhs for the year. The net profit attributable to owners reached Rs. 17,470.73 lakhs. These audited results reflect a stable growth trajectory, with the company maintaining its focus on pharmaceutical sector excellence.
Dividend Declaration
In a move to reward its investors, the Board of Directors has recommended a final dividend of Rs. 2/- per equity share, having a face value of Rs. 5/- each for the financial year ended March 31, 2026. This recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting.
Leadership and Governance Updates
The company has fortified its leadership team with key designations effective May 25, 2026. Mr. Sachin Patil has been appointed as the Head – Exports, and Mr. Rajendra Pagare has been named Head – Operations & Compliance. Both will serve as Senior Management Personnel to drive the company’s strategic goals.
Auditor Re-appointments
To ensure continuity in high-standard compliance and financial oversight, the company has re-appointed Smt. Ketki D. Visariya (Membership No. 16028) as the Cost Auditor for the financial year 2026-27. Additionally, the firm Manish Modi & Associates (Firm Registration No. 120780W) has been re-appointed as the Internal Auditor for the same period.
Source: BSE
